Evidence map›Paper›PMID 41144268›Full record

ArticleCarcinogenesis2025

The importance of data from the atomic bomb survivors for international radiological protection.

Richard Wakeford, Dominique Laurier

Abstract read
In one paragraph

Article in Carcinogenesis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Richard WakefordCentre for Occupational and Environmental Health, The University of Manchester, Manchester M13 9PL, United Kingdom.ORCID 0000-0002-2934-0987
Dominique LaurierFrench Nuclear Safety and Radiation Protection Authority (ASNR), Directorate of Health Research and Expertise, Fontenay aux Roses F-92262, France.ORCID 0000-0003-1432-4738

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidemiological studies using data from the lifetime experience of the survivors of the atomic bombings of Japan have been fundamental in shaping the international system of radiological protection since a clear excess risk of, first leukaemia and then other cancers, became apparent in the 1950s and 1960s. Cancer mortality and incidence data have been collected, collated and analysed by the Radiation Effects Research Foundation (RERF, and its predecessor, the Atomic Bomb Casualty Commission, ABCC) and the risk estimates so produced have been used subsequently by the International Commission on Radiological Protection (ICRP) to provide the main technical basis of its general recommendations, from its 1965 Recommendations to the latest 2007 Recommendations. As the database has grown with increasing follow-up of the survivors, together with continued refinement of the dosimetry system, ABCC/RERF analyses have become more sophisticated, permitting knowledge of the variation of risks for a growing number of specific types of cancer, as modified by sex, age-at-exposure and time-since-exposure/attained age. A growing database of non-cancer effects, such as diseases of the circulatory system and eye lens opacities, is also providing risk estimates. Even now, 80 years after the bombings, the survivors provide important information on risks decades after exposure at a young age. There is little doubt that recent RERF studies of cancer and non-cancer diseases in the survivors will continue to steer the ICRP in its progress towards the next Recommendations.

Indexed as

Atomic Bomb SurvivorsNeoplasms, Radiation-InducedNuclear WeaponsRadiation ProtectionDatabases, FactualHumansJapanSurvivorsatomic bomb survivorsepidemiologyhealth effectsionising radiationradiological protection

Identifiers

PMID41144268
PMCPMC12558147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.